Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome

Abstract

Ethical approval: The study was approved by the Bioethics Comitee of Facultad de Ciencias Bioquímicas y Farmacéuticas (Universidad Nacional de Rosario). Res Nº 076/2008. All participants signed the corresponding informed consent. Guarantor: SMMA Contributorship: HFP performed most assays and analysis of results, and wrote the paper. EP and CB performed some assays and collaborated in the analysis of results. JM performed patients selection for the study and aided in medical matters. MB, MJS and SMD performed sample collection and conditioning, as well as some laboratory determinations. HB performed statistical analysis. SMMA coordinated and supervised the whole study. Abstract word count: 251. Actual word count (excluding abstract and references): 2664 AbstractBackground: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis, fetal losses and thrombocytopenia associated to antiphospholipid (APL) antibodies (Abs). They are directed to phospholipids, such as cardiolipins (a-cardiolipin, ACA) and lupus anticoagulant (LA), or to complexes formed by phospholipids and protein cofactors, such as β2 glycoprotein 1 (a-β2GP1) and annexin V (a-annexin V). These auto Abs may be considered as a family of Abs involved in thrombotic events and APL activity. On the other hand, some proangiogenic factors are involved in the normal development of placental vasculature, such as the vascular endothelial growth factor (VEGF). Overexpression of VEGF receptor in its soluble form (sVEGFR-1) has been associated to a higher antiangiogenic activity. Our aim was to analyze the association between ACA, LA, a-β2GP1, a-annexin V and sVEGFR-1 with recurrent miscarriage before week 10 of gestation in women with APS. Methods: We studied 24 women (primary or secondary APS), who were divided into two groups: women with recurrent miscarriage before week 10 of gestation [M; n=12] and women with no history of fetal loss [NM; n=12]. ACA, a-β2GP1, aannexin V and sVEGF-R1 levels were assessed by ELISA, while LA was assessed by screening and confirmatory tests. Results: A significant association was observed between the number of positive biomarkers and the belonging group (p<0.05). Besides, a positive result for LA and a-β2GP1 was found to be significantly associated to the M group (p<0.05). Conclusions: LA and a-β2GP1 may be implicated in pregnancies complicated by recurrent miscarriage in women with APS.

Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion

“…These factors eventually lead to abortion, placental disease, fetal growth restriction, and other adverse pregnancy outcomes. [ 10 11 12 13 ]…”

Identification and ultrasensitive photoelectrochemical detection of LncNR_040117: a biomarker of recurrent miscarriage and antiphospholipid antibody syndrome in platelet-derived microparticles

“…The condition is associated with parental chromosomal anomalies, uterine abnormalities, endocrine factors, thrombophilia, cervical insufficiency and immunological disorders [1][2][3][4][5][6]. Of the various RM-related immunological disorders, antiphospholipid antibody syndrome (APS) is the most common [7,8]. Previous studies have revealed that platelet-derived microparticles (PMPs), small vesicles that arise from platelets, play a crucial role in mediating immune disorders [9,10].…”